Drug intelligence / Profile preview

mk-7145

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral[7]

Overview

MK‑7145 is an investigational small molecule drug developed as a renal outer medullary potassium (ROMK) channel inhibitor. It was studied for the treatment of hypertension and renal insufficiency. Preclinical studies demonstrated robust diuresis and natriuresis with blood pressure lowering effects. Clinical trials evaluated its safety and efficacy compared to furosemide in patients with moderate-to-severe renal insufficiency and heart failure[3][6][7].

Other names: 1255204-84-2UNII-M371870BYLUNII-M-371870BYLUNII-M 371870BYL5,5'-((1R,1'R)-Piperazine-1,4-diylbis(1-hydroxyethane-2,1-diyl))bis(4-methylisobenzofuran-1(3H)-one)5-[(1R)-1-hydroxy-2-[4-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methylisobenzofuranone[2][7]

Targets

KCNJ1 (Kir1.1)

Beyond the preview

Go deeper on mk-7145.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mk-7145.

Explore the full profile